| Market revenue in 2024 | USD 6.9 million |
| Market revenue in 2030 | USD 29.6 million |
| Growth rate | 27.8% (CAGR from 2025 to 2030) |
| Largest segment | Kits & reagents |
| Fastest growing segment | Kits & Reagents |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Kits & Reagents, Instruments, Services |
| Key market players worldwide | Danaher Corp, Hologic Inc, FUJIFILM Holdings Corp, Lonza Group Ltd, Miltenyi Biotec, Bio-Techne Corp, Qiagen NV, Thermo Fisher Scientific Inc, Abcam PLC, RoosterBio |
Funds offered by the Canadian government to drive innovations for the development of its healthcare sector are expected to boost the market. Canadian funding agencies are expected to play a significant role in market growth.
The Atlantic Cancer Research Institute, a Canadian nonprofit organization, has developed a highly efficient and flexible tool for the isolation and purification of exosomes from biofluids. The institute currently provides a license for the use of its exosome isolation technique to companies and research institutes for the further study of exosomes in disease management.
For instance, in March 2017, it licensed out Vn96 synthetic peptide, one of the leading technologies for the isolation of exosomes from body fluids, to biotechnology company Bio Vendor for research related to the development of tests and immunoassays.
Publish Date: May 05, 2026
Last Updated: Aug 26, 2026
No credit card required*
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| FUJIFILM Holdings Corp | View profile | 83,784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | www.fujifilmholdings.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Danaher Corp | View profile | 63,000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | www.danaher.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Hologic Inc | View profile | 6,990 | 250 Campus Drive, Marlborough, MA, United States, 01752 | www.hologic.com |
| Bio-Techne Corp | View profile | 3,050 | 614 McKinley Place N.E., Minneapolis, MN, United States, 55413 | www.bio-techne.com |
| Abcam PLC | View profile | 1,760 | Discovery Drive, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AX | www.abcam.com |
| Miltenyi Biotec | View profile | 1001-5000 | Bergisch Gladbach, Nordrhein-Westfalen, Germany, Europe | www.miltenyibiotec.com |
| RoosterBio | View profile | 1-10 | Frederick, Maryland, United States, North America | roosterbio.com |
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Exosomes Market Outlook will help companies and investors design strategic landscapes.
Kits & Reagents was the largest segment with a revenue share of 59.42% in 2024.
Horizon Databook has segmented the Canada exosomes market based on kits & reagents, instruments, services covering the revenue growth of each sub-segment from 2018 to 2030.
Funds offered by the Canadian government to drive innovations for the development of its healthcare sector are expected to boost the market. Canadian funding agencies are expected to play a significant role in market growth.
The Atlantic Cancer Research Institute, a Canadian nonprofit organization, has developed a highly efficient and flexible tool for the isolation and purification of exosomes from biofluids. The institute currently provides a license for the use of its exosome isolation technique to companies and research institutes for the further study of exosomes in disease management.
For instance, in March 2017, it licensed out Vn96 synthetic peptide, one of the leading technologies for the isolation of exosomes from body fluids, to biotechnology company Bio Vendor for research related to the development of tests and immunoassays.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada Exosomes Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Canada Exosomes Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
